Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
by on Friday, May 25th, 2012 | No Comments
Conditions: Acute Myeloid Leukemia; Chronic Myeloid Leukemia
Interventions: Drug: PRI-724; Drug: PRI-724
Sponsors: Prism Pharma Co., Ltd.; Prism Pharma Co., Ltd.; PharmaNet/i3
Not yet recruiting – verified May 2012
The rest is here: Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies